Elexacaftor + tezacaftor + ivacaftor
Elexacaftor + tezacaftor + ivacaftor has been studied in 2 papers since 2025: 1 trial and 1 observational study in people; 1 in the past year. The newest paper, Sep 18, 2026: “Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis”.
See all 2 papers on elexacaftor + tezacaftor + ivacaftor
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries.
“In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”
None of its findings points the other way.
- 2 independent labs in 2 countries
- Funders: Canada Research Chairs Program and 4 more
- 2 of 4 findings with company ties
- Human trial1
- Humans1
Studies in people
1 study gave elexacaftor + tezacaftor + ivacaftor to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
| Trialone-year follow-up | 8 peopletwo (25%) were femalemedian age of 25.4 years (IQR 22.1–28.0)Modulator-naïve pwCF | bioRxiv, Sep 18, 2026 |
What did studies of elexacaftor + tezacaftor + ivacaftor find?
3Studies of elexacaftor + tezacaftor + ivacaftor measured 3 outcomes: GrimAge2, epigenetic age and lung function.
GrimAge2
downin humans1
1 study
GrimAge2
downin humans1
Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in cystic fibrosis (P=0.008).
“DNAmGrimAge2 age acceleration decreased significantly following ETI (P=0.008; ).”
Human trialin cystic fibrosisone-year follow-upn = 8
bioRxivPreprint
Elexacaftor + tezacaftor + ivacaftor decreases GrimAge2 in humans (from 1.92 years to -1.70 years (p=0.008)).
“DNAmGrimAge2 age acceleration decreased after ETI treatment, from a median of 1.92 years before treatment to -1.70 years after 1 year (p=0.008).”
Human trial1 yearn = 8
bioRxivPreprint
Epigenetic age
upin humans1
1 study
Epigenetic age
upin humans1
Elexacaftor + tezacaftor + ivacaftor increases epigenetic age in humans.
“In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”
Human trialcystic fibrosis subjects with baseline epigenetic age lower than chronological age; reported as a tendency1 year
Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis
International journal of molecular sciences
Lung function
upin humans1
1 study
Lung function
upin humans1
Elexacaftor + tezacaftor + ivacaftor improves lung function in humans (cystic fibrosis subjects with baseline epigenetic age lower than chronological age).
“In these subjects, ETI therapy further improved lung function and tended to increase the epigenetic age”
Human trialcystic fibrosis subjects with baseline epigenetic age lower than chronological agelung1 year
Pulmonary Function Modulates Epigenetic Age in Subjects with Cystic Fibrosis
International journal of molecular sciences